- Alirocumab reduces total non-fatal and fatal cardiovascular events - …
Number of the records: 1  

Alirocumab reduces total non-fatal and fatal cardiovascular events - from the ODYSSEY OUTCOMES study

  1. Alirocumab reduces total non-fatal and fatal cardiovascular events - from the ODYSSEY OUTCOMES study = Alirokumab redukuje všetky nefatálne kardiovaskulárne príhody i fatálne príhody - pokračovanie údajov ODYSSEY OUTCOMES štúdie / Murín J., Bulas J., Wawruch M.. Cardiology letters Vol. 28, no. 2-3 (2019), s. 94-98
    article

    article

Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.